January 26, 2022

Volume XII, Number 26

Advertisement
Advertisement

January 26, 2022

Subscribe to Latest Legal News and Analysis

January 25, 2022

Subscribe to Latest Legal News and Analysis

January 24, 2022

Subscribe to Latest Legal News and Analysis

2021 Open Payments (Sunshine Act) Reporting Window Closes March 31

As a reminder to our life sciences clients including drug manufacturers, medical device manufacturers, and group purchasing organizations, all Open Payments data from the 2020 program year must be reported to CMS by no later than March 31, 2021. Organizations that participate in the Open Payments program are also reminded that they must submit a final attestation that their data is timely, complete and accurate in addition to reporting data from fiscal year 2020. Importantly, the Centers for Medicare and Medicaid Services (CMS) does not consider Open Payments data to be completely reported until the final attestation is received by CMS.

As background, the Federal Open Payments program (the “Sunshine Act”) requires certain manufacturers of drugs, medical devices, biologicals, or other medical supplies covered under the Medicare, Medicaid, or CHIP programs (as well as group purchasing organizations (GPOs) who engage in transactions with such products) to annually report the following information to CMS:

  1. Direct and indirect payments or other transfers of value made to physicians and teaching hospitals; and

  2. Certain ownership or investment interests held by physicians or their immediate family members.

In October 2020, CMS and the U.S. Department of Justice (DOJ) announced their first settlement in relation to the Open Payments program pursuant to which medical device manufacturer, Medtronic USA Inc., was required to pay over $9.2 million to resolve allegations that it violated the Open Payments program. In brief, CMS and DOJ alleged that Medtronic underreported payments it had made to a restaurant owned by a physician that Medtronic used for numerous social events. The Medtronic settlement serves as an important reminder that the federal government is becomingly increasingly savvy in enforcing Open Payments requirements and that manufacturers and other stakeholders must comply with the Open Payments program.

Finally, it is important to note that the 2021 reporting period is the final period in which Open Payments program participants will submit reporting under the current Open Payments reporting regime. Beginning Jan. 1, 2021, the Open Payments program was expanded to include five additional provider types for which manufacturers and other affected entities must track and report Open Payments data. These new provider types include: physician assistants, nurse practitioners, certified nurse-midwives, clinical nurse specialists, and certified registered nurse anesthetists (CRNAs) and anesthesiology assistants. While the 2021 Open Payments reporting cycle will not include data related to these new provider types, Open Payments program participants should currently be tracking and documenting Open Payments data for these provider types in anticipation of the 2022 reporting cycle.

© 2022 Dinsmore & Shohl LLP. All rights reserved.National Law Review, Volume XI, Number 78
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Timothy Cahill Health Care Attorney Dinsmore Law Firm
Partner Of Counsel

Tim is an attorney with more than two decades of experience in health care-related fields. He has worked as in-house counsel and external counsel for non-profit and commercial health care organizations, health systems, hospitals, physicians and physician groups, joint ventures, and other corporate clients. Most recently, Tim served in the role of general counsel of a regional health system, working closely with the executive team and board to further the organization’s strategic mission and significantly improve operating revenues.

In his practice, Tim has addressed a wide range...

614-227-4274
Brian Murray, healthcare lawyer, Dinsmore
Associate

Bryan focuses his practice on health care law and provides legal counsel to health care industry clients on a range of issues, such as specialty and mail-order pharmacy operations, provider networks and reimbursement, regulatory compliance, contract review and preparation and 340B programming. He has experience analyzing pharmaceutical trade issues affected by state and federal regulatory frameworks, including pharmacy practice acts, the anti-Kickback Statute, the Drug Supply Chain Security Act, the Stark Law and the Health Insurance Probability and Accountability Act. ...

(412) 339-5603
Advertisement
Advertisement
Advertisement